Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s490772 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Sumaiah J Alarfaj und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Fenofibrate, Colitis, Ulcerative, NLR Family, Pyrin Domain-Containing 3 Protein, Sirtuin 1. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
- Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
- Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
- Department of Biochemistry and Pharmacology, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt.
ORCID-Profile: Sumaiah J Alarfaj, Mostafa M Bahaa, Eman El-Khateeb, Amir O Hamouda, Walaa A Negm, Amsha S Alsegiani, Mamdouh Eldesoqui, Mahmoud S Abdallah
Zitieren
APA
Alarfaj, S. J., Bahaa, M. M., Elmasry, T. A., Elberri, E. I., El-Khateeb, E., Hamouda, A. O., Salahuddin, M. M., Kamal, M., Gadallah, A. A., Eltantawy, N., Yasser, M., Negm, W. A., Hamouda, M. A., Alsegiani, A. S., Alrubia, S., Eldesoqui, M., & Abdallah, M. S. (2024). Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s490772
Vancouver
Alarfaj SJ, Bahaa MM, Elmasry TA, Elberri EI, El-Khateeb E, Hamouda AO, et al. Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s490772
BibTeX
@article{Alarfaj2024,
author = {Alarfaj, Sumaiah J and Bahaa, Mostafa M and Elmasry, Thanaa A and Elberri, Eman I and El-Khateeb, Eman and Hamouda, Amir O and Salahuddin, Muhammed M and Kamal, Marwa and Gadallah, Abdel-Naser Abdel-Atty and Eltantawy, Nashwa and Yasser, Mohamed and Negm, Walaa A and Hamouda, Manal A and Alsegiani, Amsha S and Alrubia, Sarah and Eldesoqui, Mamdouh and Abdallah, Mahmoud S},
title = {Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s490772}
}
EUVIMED